Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793683 | PMC |
| http://dx.doi.org/10.1080/21505594.2023.2301573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine†.
J Travel Med
December 2024
Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.
Background: Chikungunya disease, caused by chikungunya virus (CHIKV), is associated with substantial morbidity, including debilitating CHIKV-related arthralgia.
Methods: Three clinical trials of a CHIKV vaccine (VLA1553, IXCHIQ®) were conducted in the USA: a Phase 1 dose-finding trial, a pivotal Phase 3 trial and a Phase 3 lot-to-lot consistency trial. Participants were healthy adults (≥18 years) and received a single intramuscular dose of VLA1553 (3520 participants) or placebo (1033 participants).
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.
BioDrugs
November 2024
Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis One Shields Avenue, Davis One Shields Avenue, 5327 VM3A, Davis, CA, 95616, USA.
Chikungunya virus is an emerging mosquito-borne alphavirus that causes febrile illness and arthritic disease. Chikungunya virus is endemic in 110 countries and the World Health Organization estimates that it has caused more than 2 million cases of crippling acute and chronic arthritis globally since it re-emerged in 2005. Chikungunya virus outbreaks have occurred in Africa, Asia, Indian Ocean islands, South Pacific islands, Europe, and the Americas.
View Article and Find Full Text PDFFrom bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.
J Travel Med
October 2024
Corporate Medical Affairs, Valneva SE, Ilot Saint-Joseph Bureaux Convergence, 12 ter Quai Perrache Bâtiment A, 69002 Lyon, France.
Background: Over the past 20 years, over 5 million cases of chikungunya, a mosquito-transmitted viral disease, have been reported in over 110 countries. Until recently, preventative strategies for chikungunya were largely ineffective, relying on vector control and individual avoidance of mosquito bites.
Methods: This review outlines the preclinical and clinical efficacy and safety data that led to the approval of VLA1553 (IXCHIQ®), a live-attenuated vaccine against chikungunya disease.
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection.
Vaccines (Basel)
August 2024
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Article Synopsis
- The recently licensed chikungunya vaccine, IXCHIQ, shows strong cross-neutralizing antibody responses against chikungunya virus and several related alphaviruses.
- The study measured antibody responses at one month, six months, and one year post-vaccination, revealing 100% seroconversion to most viruses tested, except for Ross River virus at 83.3%.
- IXCHIQ appears to provide antibody responses similar to natural chikungunya infections, suggesting it may offer protection to populations at risk from multiple alphavirus infections in areas where the vaccine is deployed.
Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.
J Travel Med
October 2024
Valneva Austria GmbH, Campus Vienna Biocenter, 3103 Vienna, Austria.
Background: Chikungunya is a serious and debilitating viral infection with a significant disease burden. VLA1553 (IXCHIQ®) is a live-attenuated vaccine licensed for active immunization for prevention of disease caused by chikungunya virus (CHIKV).
Methods: Immunogenicity following a single dose of VLA1553 was evaluated in healthy adults aged ≥18 years in two Phase 3 trials [N = 656 participants (per protocol analysis set)].
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!